Suvuen Life Sciences, a biopharmceutical company specializing in drug discovery and developmental activities in central nervous system disorders, has notched up net profit growth of 20.9 per cent during the fourth quarter ended March 2013 to Rs.8.63 crore as against Rs.7.15 crore in the corresponding period of last year. Its net sales improved by 18.8 per cent to Rs.74.70 crore from Rs.62.89 crore.
The board of directors has announced equity dividend of 30 per cent for the year ended March 2013 for the face value of Re. 1 per share.
For the full year its net sales increased by 26.3 per cent to Rs.257.88 crore from Rs.204.21 crore in the previous year. The sales from CRAMS increased by 18.7 per cent to Rs.227.61 crore from Rs.191.69 crore and that from services improved by 142 per cent to Rs.30.28 crore from Rs.12.52 crore. EBDITA improved by 117 per cent to Rs.54.23 crore from Rs.25.05 crore. Its net profit has taken quantum jump of 115 per cent and reached at Rs.30.84 crore from Rs.14.36 crore with an annual EPS of Rs.2.64 as against Rs.1.23 in the previous year.